Long-term Outcomes After Severe Acute Kidney Injury in Critically Ill Patients: the SALTO Study
Overview
Authors
Affiliations
Background: The extent of the consequences of an episode of severe acute kidney injury (AKI) on long-term outcome of critically ill patients remain debated. We conducted a prospective follow-up of patients included in a large multicenter clinical trial of renal replacement therapy (RRT) initiation strategy during severe AKI (the Artificial Kidney Initiation in Kidney Injury, AKIKI) to investigate long-term survival, renal outcome and health related quality of life (HRQOL). We also assessed the influence of RRT initiation strategy on these outcomes.
Results: Follow-up of patients extended from 60 days to a median of 3.35 years [interquartile range (IQR), 1.89 to 4.09] after the end of initial study. Of the 619 patients included in the AKIKI trial, 316 survived after 60 days. The overall survival rate at 3 years from inclusion was 39.4% (95% CI 35.4 to 43.4). A total of 46 patients (on the 175 with available data on long-term kidney function) experienced worsening of renal function (WRF) at the time of follow-up [overall incidence of 26%, cumulative incidence at 4 years: 20.6% (CI 95% 13.0 to 28.3)]. Fifteen patients required chronic dialysis (5% of patients who survived after day 90). Among the 226 long-term survivors, 80 (35%) answered the EQ-5D questionnaire. The median index value reported was 0.67 (IQR 0.40 to 1.00) indicating a noticeable alteration of quality of life. Initiation strategy for RRT had no effect on any long-term outcome.
Conclusion: Severe AKI in critically ill patients was associated with a high proportion of death within the first 2 months but less so during long-term follow-up. A quarter of long-term survivors experienced a WRF and suffered from a noticeable impairment of quality of life. Renal replacement therapy initiation strategy was not associated with mortality outcome.
Recovery of kidney function in acute kidney injury.
Patschan D, Stasche F, Erfurt S, Matyukhin I, Ritter O, Safi W J Nephrol. 2025; .
PMID: 40025396 DOI: 10.1007/s40620-025-02220-w.
New drugs for acute kidney injury.
Hariri G, Legrand M J Intensive Med. 2025; 5(1):3-11.
PMID: 39872831 PMC: 11763585. DOI: 10.1016/j.jointm.2024.08.001.
Prasad G, Deepankar P, Choudhary M, Ahmad A, Ram B, Kumar N Cureus. 2024; 16(6):e62690.
PMID: 39036153 PMC: 11259520. DOI: 10.7759/cureus.62690.
Gao P, Min J, Zhong L, Shao M Ren Fail. 2023; 45(2):2282708.
PMID: 37975171 PMC: 11001314. DOI: 10.1080/0886022X.2023.2282708.
Survive or thrive after ICU: what's the score?.
McNicholas B, Haines R, Ostermann M Ann Intensive Care. 2023; 13(1):43.
PMID: 37202549 PMC: 10195929. DOI: 10.1186/s13613-023-01140-x.